MobiDrop Biosciences Secures Tens of Millions in Pre-B Financing to Accelerate Commercialization and Build a World-Class Life Science Tools Platform

Recently, VCBeat learned that Mozhuo Biotechnology (Zhejiang) Co., Ltd. (hereinafter referred to as “MobiDrop”) has successfully completed a Pre-B financing round worth tens of millions of yuan. This round of financing was led byFuzhe TechnologyExclusive Investment,Dianshi CapitalAct as the exclusive financial advisor.

Over the past four years, MobiDrop has maintained an annual financing cycle, inZhouling Capital, Source Code Capital, Huagai Capital, Proxima VenturesBolstered by professional investment institutions, it has achieved rapid growth. The new round of financing will be primarily used for commercial promotion, building an internationally leading life science tools platform, and facilitating application implementation.

In 2018, MobiDrop was founded at Harvard University. Leveraging world-leading droplet microfluidics platforms and gene detection technologies, the company has deeply cultivated the life sciences tools sector, striving to become an internationally leading platform for life science tools. Currently, the company has established a diverse portfolio of platform-based product lines, including high-throughput single-cell multi-omics sequencing, microbial single-cell sequencing, and single-cell sorting, providingAn integrated solution combining instruments, chips, reagents, and bioinformatics software.

MobiDrop’s flagship product, the MobiNova®-100 high-throughput single-cell library preparation system, has broken the long-standing import monopoly on single-cell sequencing tools in China. Since its launch over a year ago, MobiDrop has gained recognition from leading scientific research service providers and pharmaceutical companies, including Novogene, BioCapital CrystalDx, LC-Bio, OE Biotech, and Biocytogen. Its products are now serving universities, research institutes, and enterprises across China.

MobiDrop MobiNova® High-Throughput Single-Cell Cross-Platform Solution

MobiDrop is at the international forefront of commercializing microfluidics technology. It has launched the world’s only high-throughput single-cell sequencing solution for microbes, expanding application scenarios; continuously reduced sample testing costs through technological upgrades and supply chain localization; and accelerated the industrial translation of innovative technologies through in-depth strategic collaborations.

Currently, MobiDrop has preliminarily established its single-cell sequencing ecosystem, comprehensively covering fields such as scientific research, drug development, assisted reproduction, tumor medication guidance, agricultural breeding, and synthetic biology.

Dr. Pei Hao, CEO of MobiDropStatement: Expressing gratitude for the trust placed in us by Zhejiang Fuzhe Technology Co., Ltd. and existing shareholders, MobiDrop will continue to deepen its efforts in building a single-cell sequencing ecosystem. Leveraging this round of financing as an opportunity, we will accelerate commercialization, expand into global markets, and persist in developing new technologies and translating them into products, with the aim of establishing an internationally leading life science tools platform. Meanwhile, we are committed to extensively applying our platform technologies to broader fields such as scientific discovery, drug development, clinical diagnostics, agriculture, and industrial applications, thereby achieving sustained and healthy company growth while contributing to human health and the development of foundational industries.

Du Zhan, General Manager of Zhejiang Fuzhe Technology Co., Ltd.It was stated that the life and health industry is one of the key sectors prioritized for development in Zhejiang Province. Aligning with the major strategies of the Provincial Party Committee and Provincial Government, and closely following the “14th Five-Year Plan” for the Development of Zhejiang’s Health Industry, Zhejiang Fuzhe Technology Co., Ltd. has actively invested in innovative enterprises with high growth potential within Zhejiang’s medical and broader healthcare sector. MobiDrop possesses original innovation capabilities, having launched the world’s first single-cell microbial sequencing technology, thereby leading industry development. We look forward to MobiDrop’s continued product innovation and market expansion, including its strategic entry into overseas markets, enabling “Intelligent Manufacturing in China” to expand from Zhejiang to the global stage.

Zhejiang Fuzhe Technology Co., Ltd. is a wholly-owned subsidiary of Zhejiang State-owned Capital Operation Co., Ltd., specializing in sci-tech innovation services, including sci-tech innovation parks, venture capital, and sci-tech finance. Leveraging a professional investment team and strong advantages in capital and project resources, the company’s subsidiary, Zhejiang Provincial Science and Technology Venture Capital Co., Ltd., was established in 1993. As one of the earliest sci-tech venture capital institutions in China, it boasts nearly 30 years of experience in equity investment and fund management. It is among the venture capital firms in the province with the highest number of portfolio companies that have completed initial public offerings (IPOs). To date, it has injected venture capital into more than 200 high-tech industry projects, with 28 of its invested companies already listed on stock exchanges.

Innovation-Driven, Excellence for the Future. MobiDrop focuses on microfluidic chip technology and independently developed genetic testing, offering platform-level product lines such as high-throughput single-cell multi-omics sequencing, microbial single-cell sequencing, and single-cell sorting. It provides integrated solutions that combine instruments, chips, reagents, and bioinformatics software. Committed to building an internationally leading life science tools platform, MobiDrop aims to promote human health and the development of foundational industries.